key: cord-1054975-5lwv1obi authors: Lee, Ken C.H.; Sewa, D. W.; Phua, G. C. title: Potential role of statins in COVID-19 date: 2020-06-02 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.05.115 sha: 8f309506fde1764d0746f7466e91ed98e1fc0034 doc_id: 1054975 cord_uid: 5lwv1obi Abstract Patients with COVID-19 infection have an increased risk of cardiovascular complications and thrombotic events. Statins are known for their pleiotropic anti-inflammatory, antithrombotic and immunomodulatory effects. They may have a potential role as adjunctive therapy to mitigate the effects of endothelial dysfunction and dysregulated inflammation in patients with COVID-19 infection. Infection with SARS-CoV-2 causes down regulation of ACE2. This increases vulnerability to the damaging effects of AT II, which is thought to be responsible for the lung injury that is seen in many COVID-19 patients. The dual roles played by ACE2 as a protector against the harmful effects of hyperinflammatory response, and as the receptor for SARS-CoV, has caused controversy regarding the use of medications such as ACE-inhibitors (ACE-I) and angiotensin-receptor blockers (ARBs). These concerns stem from experimental animal models that demonstrate these drugs cause an up regulation of ACE2 expression and activity in heart and kidney tissue 2,3 . This means patients on these drugs might be at an increased risk of more severe COVID-19 infection. Nonetheless, increased ACE2 may confer protection against more severe lung injury in patients who have been infected 4, 5 . Results from several recent observational studies, however, do not support an association between these drugs and more severe COVID-19 infection [6] [7] [8] During the 2009 H1N1 pandemic, statin therapy was associated with reduced disease severity among hospitalised patients 17 . Two observational studies reported 41% and 59% reduction in 30-day all-cause mortality respectively that were associated with the use of J o u r n a l P r e -p r o o f statins in hospitalised patients with influenza infections 18, 19 . The first study suggested that statins might be useful for treating hospitalised influenza patients 18 , while the other concluded that statins should not be used as adjunct treatment to improve survival due to unmeasured confounding in the study 19 . Nonetheless, these encouraging findings have led some to advocate statins as an immunomodulatory treatment for viral infections with potential to cause pandemics 17, 20 . Current management of patients with COVID-19 infection remains largely supportive. The most severe cases often require mechanical ventilation, and standard approaches to managing acute respiratory distress syndrome (ARDS) of any cause are often used to treat these patients. However, increasing data suggest the respiratory failure that develops in COVID-19 infection differs from that in other ARDS patients in many ways 21 . Features including a relatively good lung compliance despite poor oxygenation, the lack of pulmonary vasoconstriction with resultant significant shunting, and thrombotic microangiopathy [22] [23] [24] suggest that vascular endothelial dysfunction plays in important role in the pathogenesis for COVID-19 infections 25 . Statin treatment might improve endothelial and vascular function in these patients. In fact, combination of statin/ARB treatments was used in an unconventional and poorly documented experience to target the host response and prevent endothelial barrier damage in Ebola patients during the outbreak in West Africa 26, 27 . A similar approach might be considered for patients with severe COVID-19 infection since both statins and ARBs upregulate ACE2 activity and counter endothelial dysfunction 28 . Markedly elevated D-dimer levels and high incidence of thrombotic complications recently reported in critically ill COVID-19 patients have also raised concerns about increased thrombogenicity in these patients 29, 30 . One study reported a 31% cumulative incidence of thrombotic complications among 184 patients with COVID-19 pneumonia admitted to the intensive care unit despite standard pharmacological thromboprophylaxis 30 . Some centres recommend prophylactic anticoagulation for all patients with COVID-19 infection, and J o u r n a l P r e -p r o o f therapeutic anticoagulation to be strongly considered for patients deemed to be high risk for coagulopathy. Others have proposed thrombolytic treatment in refractory cases of hypoxia 31 . The role of statins in managing venous thromboembolism has been explored in previous studies. The JUPITER trial, which studied relatively healthy patients with high CRP levels, reported a significantly decreased rate of deep vein thrombosis in those who received rosuvastatin compared to placebo 32 . Another study found statin therapy was associated with 50% reduction in recurrent pulmonary embolism 33 To conclude, we believe that statins might mitigate the effects of COVID-19 infection in certain patients based on our understanding of its associated coagulopathy, endothelial J o u r n a l P r e -p r o o f dysfunction and dysregulated inflammation. However, in the absence of reliable evidence, the role of statins remains uncertain and this undoubtedly contributes to the hesitancy to administer a yet unproven treatment. Phase 3 trials should be considered to determine which COVID-19 patients may benefit from statin therapy, and the type and dose of statin to be given. Declaration-of-competing-interests Angiotensin-converting enzyme (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Effects of renin-angiotensin system blockade on renin angiotensin-(1-7) forming enzymes and receptors Angiotensin-converting enzyme 2 protects from severe acute lung failure A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Cardiovascular disease, drug therapy, and mortality in Covid-19 Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19 Renin-angiotensin-aldosterone system blockers and the risk of Covid-19 Position statement of the ESC Council on hypertension on ACEinhibitors and angiotensin receptor blockers HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Treating influenza with statins and other immunomodulatory agents Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study laboratory-confirmed influenza hospitalizations. Open Forum Infect Dis Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola Clinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia COVID-19 coagulopathy in Caucasian patients Endothelial cell infection and endotheliitis in COVID-19 Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers What treating Ebola means for pandemic influenza Hiding in plain sight: an approach to treating patients with severe COVID-19 infection Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 Incidence of thrombotic complications in critically ill ICU patients with COVID-19 COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. medRxiv A randomized trial of rosuvastatin in the prevention of venous thromboembolism: the JUPITER trial Statin treatment and the risk of recurrent pulmonary embolism Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective Failure of statins in ARDS: the quest for the Holy Grail continues Characteristics and mechanism of liver injury in 2019 coronavirus disease The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Ethical approval is not required for the preparation of this manuscript.